OAC
VRCA icon

OMERS Administration Corp’s Verrica Pharmaceuticals VRCA Stock Holding History

OMERS Administration Corp’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,600
Closed -$188K – 1177
2025
Q4 		$188K Buy
+22,600
New +$125K ﹤0.01% 919

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OMERS Administration Corp's VRCA Position: Q1 2026 in Review

OMERS Administration Corp sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 22,600 shares — an estimated $188K sold.

OMERS Administration Corp first reported a position in VRCA in Q4 2025 and held it in 1 quarter. The position peaked at $188K in Q4 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • OMERS Administration Corp reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 22,600 Verrica Pharmaceuticals shares in Q1 2026, an estimated $188K.
  • OMERS Administration Corp first reported a position in Verrica Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Verrica Pharmaceuticals position peaked at $188K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.